Tracer library / [177Lu]Lu-PSMA-1-DOTA
Structure of PSMA-1-DOTA (unlabelled parent compound, from PubChem)
Unlabelled parent compoundPubChem CID 177864543

[177Lu]Lu-PSMA-1-DOTA

Also written as [Lu-177]Lu-PSMA-1-DOTA
Radionuclide
Lu-177 t½ 9584.6 min
Modality
Therapy
Production route
—
Stage
Clinical research
Syntheses indexed
1
Prostate cancerPSMA-directed radioligand therapy

What it is

Compound class
PSMA-targeting urea-based small molecule with DOTA chelator
Target / mechanism
PSMA (prostate-specific membrane antigen) targeting ligand PMID 40897948
Clinical application
PSMA-targeted radioligand therapy of prostate cancer PMID 40897948
Theranostic pair
[68Ga]PSMA-1-DOTA

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesis—none>95%>94%PSMA-1-DOTA40897948
2025 Mol Imaging Biol
A stock solution of 177Lu (Eckert & Ziegler) in 0.04 M HCl was prepared in a clean reaction vial. - Typically, a crude yield of > 95% and a radiochemical purity > 94% were achieved.

Need this precursor?We can point you to suppliers for [177Lu]Lu-PSMA-1-DOTA, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 40897948. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 40897948: 'PSMA-1-DOTA'. Stage set/updated at stage 23 from PMID 40897948: 'A compassionate use PET imaging study on a patient with metastatic castration-resistant prostate cancer was performed using [68 Ga]Ga-PSMA-1-DOTA.'. | Stage 30 (2026-09-18): Stage was 'compassionate use'; normalised to 'Clinical research', original wording kept here.
Ask a question